ArticleJournal of Crohn's & colitis2026
The CONTEXT trial: Real world clinical use of GIQuant-a motility MRI based activity biomarker for small bowel Crohn's disease.
Article in Journal of Crohn's & colitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
backgroundMotility MRI is a validated marker of small bowel Crohn's disease (CD) activity. Objective assessment of small bowel motility with GIQuant (Motilent, London, U.K.) may have a valuable role to play in personalised patient care. The aim of this study was to assess the impact of implementing GIQuant on clinical impressions around treatment response in small bowel CD.
methodsPatients with small bowel CD on or starting therapy underwent two MRE scans (∼1 year apart) including motility MRI (mMRI) imaging. Twelve gastroenterologists from six U.K. participating centres evaluated patient response based on standard of care tests, grading them on a 6-point scale (much/somewhat/slightly worse through to slightly/somewhat/much better). After initial assessment, GIQuant scores and percentage change were revealed to the gastroenterologist who then updated their response assessment with this information. GIQuant scores at baseline and follow up are reported along with magnitude of change in clinically categorised responders and non-responders.
resultsOver the study period of 3.6 years a total of 253 patients (61% male), with ileal (52%) or ileocolonic (48%) CD underwent 506 MRE scans, with a median 10.4-month gap (range 2 to 36) between scans.In 120/253 (47%) patients, gastroenterologists reported a change in their impression of patient status (one step change or greater) after reviewing the GIQuant results with 55/253 (22%) reversing their overall assessment (between deterioration or improvement) across the two time points.In clinical responders, the GIQuant score increased from 123 to 163 (32% increase), P < .001 with non-responders showing a 2 point decrease in score (P = .9).
conclusionGIQuant as a measure of motility MRI demonstrated robust utility to track the response of small bowel Crohn's activity to therapeutic intervention across time points.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.